Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 021629
Company: SANOFI AVENTIS US

- This Former NDA Was Deemed To Be a BLA on March 23, 2020.

Products on BLA 021629

CSV | Excel | Print

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
APIDRA	INSULIN GLULISINE RECOMBINANT	1000 UNITS/10ML (100 UNITS/ML)	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	Prescription	None	No	No
APIDRA	INSULIN GLULISINE RECOMBINANT	300 UNITS/3ML (100 UNITS/ML)	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	Discontinued	None	No	No
APIDRA SOLOSTAR	INSULIN GLULISINE RECOMBINANT	300 UNITS/3ML	INJECTABLE;SUBCUTANEOUS	Prescription	None	No	No

Showing 1 to 3 of 3 entries

Approval Date(s) and History, Letters, Labels, Reviews for BLA 021629

Labels for BLA 021629

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
1-888-INFO-FDA (1-888-463-6332)
Contact FDA